PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.34%
Revenue growth above 1.5x MRVL's 6.88%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
40.10%
Gross profit growth above 1.5x MRVL's 9.28%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
452.27%
EBIT growth above 1.5x MRVL's 0.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
452.27%
Operating income growth above 1.5x MRVL's 0.09%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
350.00%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
350.00%
EPS growth of 350.00% while MRVL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
350.00%
Diluted EPS growth of 350.00% while MRVL is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.11%
Dividend growth of 18.11% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
30.74%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
19.32%
FCF growth under 50% of MRVL's 87.66%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-23.21%
Negative 10Y revenue/share CAGR while MRVL stands at 3.03%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-31.88%
Negative 5Y CAGR while MRVL stands at 3.03%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-23.85%
Negative 3Y CAGR while MRVL stands at 3.03%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
92.96%
10Y OCF/share CAGR above 1.5x MRVL's 50.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-48.34%
Negative 5Y OCF/share CAGR while MRVL is at 50.15%. Joel Greenblatt would question the firm’s operational model or cost structure.
5.65%
3Y OCF/share CAGR under 50% of MRVL's 50.15%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-12.50%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-69.24%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-75.71%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
285.89%
Below 50% of MRVL's 675.09%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
105.52%
Below 50% of MRVL's 675.09%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
42.79%
Below 50% of MRVL's 675.09%. Michael Burry suspects a serious short-term disadvantage in building book value.
15.92%
Dividend/share CAGR of 15.92% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
6.77%
Dividend/share CAGR of 6.77% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
8.43%
3Y dividend/share CAGR of 8.43% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
22.90%
Our AR growth while MRVL is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
6.77%
Inventory growth well above MRVL's 1.95%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-3.53%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-3.98%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
4.12%
R&D dropping or stable vs. MRVL's 8.86%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
11.32%
SG&A growth well above MRVL's 10.43%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.